{"id":56980,"date":"2026-02-12T21:25:39","date_gmt":"2026-02-12T13:25:39","guid":{"rendered":"https:\/\/flcube.com\/?p=56980"},"modified":"2026-02-12T21:25:40","modified_gmt":"2026-02-12T13:25:40","slug":"eli-lillys-mounjaro-wins-nmpa-monotherapy-approval-for-type-2-diabetes-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56980","title":{"rendered":"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE:\u202fLLY<\/a><\/strong>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>Mounjaro (tirzepatide)<\/strong> as a <strong>monotherapy for type 2 diabetes (T2D)<\/strong> in China. The authorization, based on the <strong>SURPASS-CN-MONO study<\/strong> demonstrating <strong>statistically significant HbA1c, body weight, and fasting glucose improvements<\/strong>, completes <strong>evidence coverage<\/strong> for tirzepatide across <strong>both monotherapy and combination therapy scenarios<\/strong> in the <strong>world&#8217;s largest diabetes market<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Eli Lilly and Company (NYSE:\u202fLLY)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Mounjaro (tirzepatide) \u2013 Dual GIP\/GLP-1 receptor agonist<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td><strong>Monotherapy for type 2 diabetes<\/strong><\/td><\/tr><tr><td><strong>Prior China Approvals<\/strong><\/td><td>Combination therapy for T2D (2024); obesity (Zepbound, 2025)<\/td><\/tr><tr><td><strong>Evidence Base<\/strong><\/td><td>SURPASS-CN-MONO study (40-week, 206 Chinese participants)<\/td><\/tr><tr><td><strong>Strategic Significance<\/strong><\/td><td><strong>Complete T2D evidence coverage<\/strong> (mono + combo) for China market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-surpass-cn-mono-study\">Clinical Evidence \u2013 SURPASS-CN-MONO Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Tirzepatide (All Doses) vs. Placebo<\/th><th>Clinical Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>HbA1c Reduction<\/strong><\/td><td><strong>Statistically significant improvement<\/strong><\/td><td>Primary endpoint met; superior glycemic control<\/td><\/tr><tr><td><strong>Body Weight Loss<\/strong><\/td><td><strong>Statistically significant reduction<\/strong><\/td><td>Dual metabolic benefit (glycemic + weight)<\/td><\/tr><tr><td><strong>Fasting Plasma Glucose<\/strong><\/td><td><strong>Statistically significant decrease<\/strong><\/td><td>Comprehensive glucose management<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with prior SURPASS studies<\/td><td>Established tolerability; no severe hypoglycemia<\/td><\/tr><tr><td><strong>Adverse Events<\/strong><\/td><td>GI events (mild-moderate) most common<\/td><td>Manageable; no treatment discontinuation signal<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Population:<\/strong> Treatment-na\u00efve T2D patients (HbA1c 7.0-9.5%, BMI \u226523, no prior glucose-lowering drugs) \u2013 <strong>represents early intervention opportunity<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-positioning\">Market Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>China Diabetes Burden<\/strong><\/td><td><strong>&gt;140 million T2D patients<\/strong>; <strong>&lt;50% achieve glycemic targets<\/strong>; massive unmet need for effective, weight-friendly therapies<\/td><\/tr><tr><td><strong>Tirzepatide Differentiation<\/strong><\/td><td><strong>Dual GIP\/GLP-1 mechanism<\/strong> offers <strong>superior HbA1c and weight reduction<\/strong> vs. semaglutide; <strong>monotherapy approval<\/strong> expands prescriber flexibility<\/td><\/tr><tr><td><strong>Novo Nordisk Competition<\/strong><\/td><td><strong>Ozempic\/Wegovy<\/strong> (semaglutide) established but <strong>supply-constrained<\/strong>; tirzepatide <strong>manufacturing scale and efficacy advantage<\/strong> positions for market share capture<\/td><\/tr><tr><td><strong>NRDL Pathway<\/strong><\/td><td><strong>Monotherapy + combination + obesity (Zepbound)<\/strong> approvals create <strong>comprehensive reimbursement negotiation leverage<\/strong> for 2026-2027 NRDL inclusion<\/td><\/tr><tr><td><strong>Early Treatment Paradigm<\/strong><\/td><td><strong>Treatment-na\u00efve patient positioning<\/strong> (SURPASS-CN-MONO) enables <strong>first-line therapy<\/strong> capture vs. metformin escalation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-amp-competitive-outlook\">Commercial &amp; Competitive Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Priority<\/th><th>Execution Plan<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Launch<\/strong><\/td><td>Hospital and clinic promotion; endocrinologist education<\/td><td>Q1-Q2\u202f2026<\/td><\/tr><tr><td><strong>Reimbursement<\/strong><\/td><td>NRDL negotiation for T2D mono + combo indications<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Market Share<\/strong><\/td><td>Position as <strong>first-line injectable<\/strong> after metformin failure; <strong>weight benefit differentiation<\/strong><\/td><td>2026-2028<\/td><\/tr><tr><td><strong>Obesity Synergy<\/strong><\/td><td>Zepbound (tirzepatide obesity branding) cross-promotion with Mounjaro<\/td><td>Ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Mounjaro commercial performance in China, NRDL reimbursement outcomes, and competitive dynamics with Novo Nordisk semaglutide. Actual results may differ due to pricing pressure from national procurement programs, manufacturing capacity constraints, and physician adoption curves for dual GIP\/GLP-1 therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56981,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,199,4445,911,15],"class_list":["post-56980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-eli-lilly","tag-metabolic-disease","tag-nyse-lly","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Mounjaro (tirzepatide) as a monotherapy for type 2 diabetes (T2D) in China. The authorization, based on the SURPASS-CN-MONO study demonstrating statistically significant HbA1c, body weight, and fasting glucose improvements, completes evidence coverage for tirzepatide across both monotherapy and combination therapy scenarios in the world&#039;s largest diabetes market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56980\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Mounjaro (tirzepatide) as a monotherapy for type 2 diabetes (T2D) in China. The authorization, based on the SURPASS-CN-MONO study demonstrating statistically significant HbA1c, body weight, and fasting glucose improvements, completes evidence coverage for tirzepatide across both monotherapy and combination therapy scenarios in the world&#039;s largest diabetes market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56980\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T13:25:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-12T13:25:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China\",\"datePublished\":\"2026-02-12T13:25:39+00:00\",\"dateModified\":\"2026-02-12T13:25:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980\"},\"wordCount\":423,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1202.webp\",\"keywords\":[\"Diabetes\",\"Eli Lilly\",\"Metabolic disease\",\"NYSE: LLY\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56980#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56980\",\"name\":\"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1202.webp\",\"datePublished\":\"2026-02-12T13:25:39+00:00\",\"dateModified\":\"2026-02-12T13:25:40+00:00\",\"description\":\"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Mounjaro (tirzepatide) as a monotherapy for type 2 diabetes (T2D) in China. The authorization, based on the SURPASS-CN-MONO study demonstrating statistically significant HbA1c, body weight, and fasting glucose improvements, completes evidence coverage for tirzepatide across both monotherapy and combination therapy scenarios in the world's largest diabetes market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56980\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1202.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56980#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Mounjaro (tirzepatide) as a monotherapy for type 2 diabetes (T2D) in China. The authorization, based on the SURPASS-CN-MONO study demonstrating statistically significant HbA1c, body weight, and fasting glucose improvements, completes evidence coverage for tirzepatide across both monotherapy and combination therapy scenarios in the world's largest diabetes market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56980","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China","og_description":"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Mounjaro (tirzepatide) as a monotherapy for type 2 diabetes (T2D) in China. The authorization, based on the SURPASS-CN-MONO study demonstrating statistically significant HbA1c, body weight, and fasting glucose improvements, completes evidence coverage for tirzepatide across both monotherapy and combination therapy scenarios in the world's largest diabetes market.","og_url":"https:\/\/flcube.com\/?p=56980","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-12T13:25:39+00:00","article_modified_time":"2026-02-12T13:25:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56980#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56980"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China","datePublished":"2026-02-12T13:25:39+00:00","dateModified":"2026-02-12T13:25:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56980"},"wordCount":423,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56980#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1202.webp","keywords":["Diabetes","Eli Lilly","Metabolic disease","NYSE: LLY","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56980#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56980","url":"https:\/\/flcube.com\/?p=56980","name":"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56980#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56980#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1202.webp","datePublished":"2026-02-12T13:25:39+00:00","dateModified":"2026-02-12T13:25:40+00:00","description":"Eli Lilly and Company (NYSE:\u202fLLY) announced that the National Medical Products Administration (NMPA) has approved Mounjaro (tirzepatide) as a monotherapy for type 2 diabetes (T2D) in China. The authorization, based on the SURPASS-CN-MONO study demonstrating statistically significant HbA1c, body weight, and fasting glucose improvements, completes evidence coverage for tirzepatide across both monotherapy and combination therapy scenarios in the world's largest diabetes market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56980#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56980"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56980#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1202.webp","width":1080,"height":608,"caption":"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56980#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly\u2019s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56980"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56980\/revisions"}],"predecessor-version":[{"id":56982,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56980\/revisions\/56982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56981"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}